Literature DB >> 16771912

Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan.

Kazunori Oishi1, Hiroyuki Yoshimine, Hiroshi Watanabe, Kiwao Watanabe, Susumu Tanimura, Kenji Kawakami, Akitaka Iwagaki, Hideaki Nagai, Hajime Goto, Shoji Kudoh, Takayuki Kuriyama, Yoshinosuke Fukuchi, Toshiharu Matsushima, Kaoru Shimada, Keizo Matsumoto, Tsuyoshi Nagatake.   

Abstract

BACKGROUND: A high frequency of drug-resistant pneumococci has been reported in Asian countries. Few data on the drug-resistance or serotype of pneumococcal strains responsible for community-acquired pneumonia (CAP), however, are available for the past two decades in Japan.
METHODOLOGY: Susceptibility to antibiotics and the genotype of antibiotic-resistant genes and serotypes of Streptococcus pneumoniae isolates from 114 adult patients with CAP were examined in a nationwide study in Japan between 2001 and 2003.
RESULTS: Most of the cases were non-bacteraemic pneumonia and the case fatality rate was 4.4%. The most frequent genotype of the pbp gene was pbp1a + 2x + 2b (gPRSP; 36.8%) followed by pbp 2x (28.1%) and of the macrolide-resistant gene, it was ermB (50.0%). The most common serotype was 19F (29.1%), followed by serotype 23F (13.2%), 6B (12.3%) and 3 (11.4%). The coverage of serotypes of isolates by a 23-valent pneumococcal polysaccharide vaccine (PPV) would be 82.5% in these patients with CAP. Most of strains with serotypes 19F and 23F were gPRSP. A cluster of serotype 3 strains associated with the pbp 2x and ermB gene was also noted.
CONCLUSION: A high frequency of altered pbp gene mutations or of macrolide-related genes and a high serotype coverage by the 23-valent PPV found in our study of pneumococcal pneumonia facilitates attempts to increase the coverage rate of the 23-valent PPV in adults older than 65 years in Japan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16771912     DOI: 10.1111/j.1440-1843.2006.00867.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  11 in total

1.  Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination.

Authors:  Meng Chen; Yuki Hisatomi; Akitsugu Furumoto; Kenji Kawakami; Hironori Masaki; Tsuyoshi Nagatake; Yoshiko Sueyasu; Tomoaki Iwanaga; Hisamichi Aizawa; Kazunori Oishi
Journal:  Clin Vaccine Immunol       Date:  2006-12-13

Review 2.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  PfbA, a novel plasmin- and fibronectin-binding protein of Streptococcus pneumoniae, contributes to fibronectin-dependent adhesion and antiphagocytosis.

Authors:  Masaya Yamaguchi; Yutaka Terao; Yuka Mori; Shigeyuki Hamada; Shigetada Kawabata
Journal:  J Biol Chem       Date:  2008-10-30       Impact factor: 5.157

4.  Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.

Authors:  Nobuharu Ohshima; Yukihiro Akeda; Hideaki Nagai; Kazunori Oishi
Journal:  Hum Vaccin Immunother       Date:  2020-02-12       Impact factor: 3.452

5.  Interrupted time-series analyses of routine vaccination program for elderly pneumonia patients in Japan; an ecological study using aggregated nationwide inpatient data.

Authors:  Koichi Kobayashi; Taisuke Jo; Wataru Mimura; Maho Suzukawa; Nobuharu Ohshima; Goh Tanaka; Manabu Akazawa; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga; Takahide Nagase; Hideaki Nagai
Journal:  Hum Vaccin Immunother       Date:  2021-04-20       Impact factor: 3.452

6.  Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Takao Sugiyama; Yojiro Kawabe; Masao Katayama; Yasuo Suenaga; Akira Okamoto; Hisaji Ohshima; Yasumasa Okada; Kenji Ichikawa; Shigeru Yoshizawa; Kenji Kawakami; Toshihiro Matsui; Hiroshi Furukawa; Kazunori Oishi
Journal:  Arthritis Res Ther       Date:  2015-06-03       Impact factor: 5.156

7.  Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Hideko Kozuru; Yuka Jiuchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Naoya Mori; Akinori Matsumori; Koichiro Takahi; Shigeru Yoshizawa; Yojiro Kawabe; Yasuo Suenaga; Tetsuo Ozawa; Norikazu Hamada; Yasuhiro Komiya; Toshihiro Matsui; Hiroshi Furukawa; Kazunori Oishi
Journal:  Arthritis Res Ther       Date:  2015-12-10       Impact factor: 5.156

8.  Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.

Authors:  Kei Nakashima; Masahiro Aoshima; Satoko Ohfuji; Satoshi Yamawaki; Masahiro Nemoto; Shinya Hasegawa; Satoshi Noma; Masafumi Misawa; Naoto Hosokawa; Makito Yaegashi; Yoshihito Otsuka
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452

9.  Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy.

Authors:  Shunsuke Mori; Yukitaka Ueki; Yukihiro Akeda; Naoyuki Hirakata; Motohiro Oribe; Yoshiki Shiohira; Toshihiko Hidaka; Kazunori Oishi
Journal:  Ann Rheum Dis       Date:  2013-01-23       Impact factor: 19.103

10.  Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Yuka Jiuchi; Hideko Kozuru; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Naoya Mori; Akinori Matsumori; Kiyoki Kitagawa; Koichiro Takahi; Tetsuo Ozawa; Norikazu Hamada; Kyoichi Nakajima; Hideaki Nagai; Norio Tamura; Yasuo Suenaga; Masaharu Kawabata; Toshihiro Matsui; Hiroshi Furukawa; Kenji Kawakami; Kazunori Oishi
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.